Enmetazobactam is a beta-lactamase inhibitor used to treat complicated urinary tract infections in combination with cefepime. Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.
- Mechanism
- Curator reviewed · 3 references
Extended-spectrum beta-lactamases (ESBLs) are a group of bacterial serine beta-lactamases that hydrolyze third-generation cephalosporins (3GC), leading to the development of 3GC-resistant bacteria. When used in combination with cefepime, enmetazobactam protects cefepime from degradation by ESBLs and prevents antibiotic resistance.
- Primary indication
- In combination with cefepime, enmetazobactam is indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms.Curator reviewed · 1 structured indication
- Formula / weight
- C11H14N4O5S · 314.32 g/mol (avg)
- First approval
- United States, 2024 · European Union, 2024
- Also known as
- (2s,3s,5r)-3-methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate · 1h-1,2,3-triazolium, 3-(((2s,3s,5r)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt
- Code names
- AAI-101 · OCID-5090
- Brand names
Resolves to
HFZITXBUTWITPT-YWVKMMECSA-NSMILES[H][C@@]12CC(=O)N1[C@@H](C([O-])=O)[C@](C)(CN1C=C[N+](C)=N1)S2(=O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Enmetazobactam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account